Moderna's Combination Flu/COVID Vaccine Shows Promise in Early Trial

In a Phase 1/2 trial, Moderna's combination flu/COVID-19 vaccine elicited strong immune responses and was safe. The company plans a Phase 3 trial in adults 50+ this year.

The vaccine achieved antibody levels similar to or greater than licensed flu shots and updated COVID-19 vaccines. No new safety concerns were identified.

Moderna is targeting 2025 for potential regulatory approval of the combination vaccine.

Combination vaccines could improve experience, compliance, and value for health systems in fighting respiratory viruses.

Uptake of a combination vaccine may improve compared to separate flu and COVID-19 vaccines, but safety with combining vaccines remains a consideration.